NCT04107181 Pilot Study for Speculum Free Cervical Cancer Screening
| NCT ID | NCT04107181 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duke University |
| Condition | Cervical Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 305 participants |
| Start Date | 2016-04-14 |
| Primary Completion | 2028-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 305 participants in total. It began in 2016-04-14 with a primary completion date of 2028-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the work described in this protocol is to determine the optical signatures of cervical dysplasia using optical technologies.
Eligibility Criteria
Inclusion Criteria: Healthy female * Aged 21-65 years * Have had a pelvic exam * Have conversational proficiency in English * Highest level of education attained Exclusion Criteria: \- Pregnant women
Contact & Investigator
Nimmi Ramanujam, PhD
PRINCIPAL INVESTIGATOR
Duke
Frequently Asked Questions
Who can join the NCT04107181 clinical trial?
This trial is open to female participants only, aged 21 Years or older, up to 65 Years, studying Cervical Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04107181 currently recruiting?
Yes, NCT04107181 is actively recruiting participants. Contact the research team at nimmi@duke.edu for enrollment information.
Where is the NCT04107181 trial being conducted?
This trial is being conducted at Durham, United States.
Who is sponsoring the NCT04107181 clinical trial?
NCT04107181 is sponsored by Duke University. The principal investigator is Nimmi Ramanujam, PhD at Duke. The trial plans to enroll 305 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.